Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention

AIMS: Clopidogrel has, for long time, been accepted as the standard treatment for patients who have undergone a percutaneous coronary intervention (PCI). The introduction of prasugrel—and more recently, ticagrelor—has introduced a decision-making problem for clinicians and governments worldwide: to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wisløff, Torbjørn, Atar, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862019/
https://www.ncbi.nlm.nih.gov/pubmed/29474586
http://dx.doi.org/10.1093/ehjqcco/qcv023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862019/
https://www.ncbi.nlm.nih.gov/pubmed/29474586
http://dx.doi.org/10.1093/ehjqcco/qcv023

Ejemplares similares